Acarbose belongs to the α-glucosidase inhibitor class of hypoglycemic drugs, and its pharmacological action is to inhibit the activity of glycosidase in the intestinal tract, thus delaying the digestion and absorption of carbohydrates, and helping to reduce postprandial blood glucose. The drug has little intestinal absorption and usually has no systemic toxicity, but it should still be used with caution in patients with hepatic and renal insufficiency. It should not be used in people with gastrointestinal dysfunction, pregnant women, lactating women and children. Common adverse reactions to this drug are gastrointestinal reactions such as bloating, increased gas or diarrhea. Starting with a small dose and gradually increasing the dosage is an effective way to minimize adverse reactions. Acarbose needs to be based on blood glucose, under the guidance of the doctor, do not blindly use the drug, so as not to delay the condition.